English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/215708
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Lipid Vesicles Loaded with an HIV-1 Fusion Inhibitor Peptide as a Potential Microbicide

AuthorsSánchez-López, Elena; Paús, Anna; Pérez-Pomeda, Ignacio ; Calpena, A.; Haro Villar, Isabel ; Gómara Elena, María José
KeywordsMicrobicides
Drug delivery system
Nanoparticle
Fusion inhibitor peptide
Vaginal mucosa
Issue Date31-May-2020
PublisherMultidisciplinary Digital Publishing Institute
CitationPharmaceutics 12(6): 502 (2020)
AbstractThe effective use of fusion inhibitor peptides against cervical and colorectal infections requires the development of sustained release formulations. In this work we comparatively study two different formulations based on polymeric nanoparticles and lipid vesicles to propose a suitable delivery nanosystem for releasing an HIV-1 fusion inhibitor peptide in vaginal mucosa. Polymeric nanoparticles of poly-d,l-lactic-co-glycolic acid (PLGA) and lipid large unilamellar vesicles loaded with the inhibitor peptide were prepared. Both formulations showed average sizes and polydispersity index values corresponding to monodisperse systems appropriate for vaginal permeation. High entrapment efficiency of the inhibitor peptide was achieved in lipid vesicles, which was probably due to the peptide’s hydrophobic nature. In addition, both nanocarriers remained stable after two weeks stored at 4 °C. While PLGA nanoparticles (NPs) did not show any delay in peptide release, lipid vesicles demonstrated favorably prolonged release of the peptide. Lipid vesicles were shown to improve the retention of the peptide on ex vivo vaginal tissue in a concentration sufficient to exert its pharmacological effect. Thus, the small size of lipid vesicles, their lipid-based composition as well as their ability to enhance peptide penetration on vaginal tissue led us to consider this formulation as a better nanosystem than polymeric nanoparticles for the sustained delivery of the HIV-1 fusion inhibitor peptide in vaginal tissues.
Description© 2020 by the authors.
Publisher version (URL)https://doi.org/10.3390/pharmaceutics12060502
URIhttp://hdl.handle.net/10261/215708
DOI10.3390/pharmaceutics12060502
ISSN1999-4923
E-ISSN1999-4923
Appears in Collections:(IQAC) Artículos
Files in This Item:
File Description SizeFormat 
Lipid_Sanchez_Lopez_Art2020.pdf903,07 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.